Hongjie Wang, Chang Li, Adebimpe Obadan, Hannah Frizzell, Tien-Ying Hsiang, Sucheol Gil, Audrey Germond, Connie Fountain, Audrey Baldessari, Steve Roffler, Hans-Peter Kiem, Deborah Fuller, Andre Lieber
While SARS-CoV2 vaccines have shown an unprecedented success, the ongoing emergence of new variants and necessity to adjust vaccines justifies the development of alternative prophylaxis and therapy approaches. Hematopoietic stem cell (HSC) gene therapy using a secreted CoV2 decoy receptor protein (sACE2-Ig) would involve a one-time intervention resulting in long-term protection against airway infection, viremia, and extrapulmonary symptoms. We recently developed a technically simple and portable in vivo hematopoietic HSC transduction approach that involves HSC mobilization from the bone marrow into the peripheral blood stream and the intravenous injection of an integrating, helper-dependent adenovirus (HDAd5/35++) vector system...
January 21, 2022: Human Gene Therapy